Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Questionnaire application for JIA cases and their parents: Scales will be applied to cases diagnosed with JIA and their parents
Study summary
Juvenile idiopathic arthritis (JIA) is the primary rheumatic disease reported to affect the pediatric population. Research suggests that parents' thoughts and feelings about their child's pain, specifically with JIA diagnosis, may influence treatment compliance. Considering that this situation may also affect children's adherence to treatment, the identification and management of parents' catastrophizing of pain is emphasized as important in improving treatment outcomes. This study aimed to examine the biopsychosocial characteristics of parents of children diagnosed with JIA according to their reported catastrophizing of pain.
Eligibility
Primary outcome measure(s)
- Pain Catastrophizing Scale-Parent (PCS-P) — Baseline
It is assessed using a 5-point Likert scale ranging from 0 (never) to 4 (always) and consists of 13 items. Similar to the child questionnaire, it assesses 3 domains: rumination, magnification, and helplessness. A total score between 0 and 52 is obtained; higher scores reflect a higher level of catastrophizing in parents. - Pain Catastrophizing Scale-Children (PCS-C) — Baseline
Consists of 13 items that describe the different thoughts and feelings children may experience when they feel pain. The questionnaire measures three domains: rumination, magnification, and helplessness. All items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (always). Higher scores indicate more catastrophic pain beliefs. The total score ranges from 0 to 52.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hacettepe University | Çankaya | Ankara | Recruiting |
More Hacettepe University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07185750 on ClinicalTrials.gov ↗ ← All trials in Turkey